Advertisement

Pharmacy World & Science

, Volume 29, Issue 6, pp 635–640 | Cite as

Do Finnish women using hormone replacement therapy need more information about risks

  • Miia J. TiihonenEmail author
  • Anna-Mari Heikkinen
  • Riitta S. Ahonen
Research Article

Abstract

Objective

In 1998, the Women’s Health Initiative (WHI) in 2002 and the Million Women Study (MWS) in 2003 have shown a need for re-evaluation of the benefits and adverse reactions of hormone replacement therapy (HRT). Consequently the authorities in Europe and USA have issued new recommendations against the use of HRT. The aim of this study was to examine women’s perceptions of HRT since the publication of the Women’s Health Initiative study and the Million Women Study, and the kind of sources women use to obtain information about HRT.

Method

The data was collected with questionnaire survey in the autumn 2003 among 315 women using HRT.

Results

One third of the respondents (35%) had experienced fears concerning HRT use, and more than half (52%) reported that the debate in the media had markedly influenced them; they have experienced fears or worries, considered discontinuation or discussed with the physician. Whereas the most common source of information concerning the benefits of HRT was the physician (74%), the most common source of information concerning the risks of HRT was the media (78%).

Conclusion

This study shows that women using HRT should get more information about the risks from health care professionals. Physicians and pharmacists have an opportunity to alleviate fears and to help women to critically evaluate the information they get from the media. Such discussions are also important to women who have been using HRT for years.

Keywords

Counselling Finland Hormone replacement therapy HRT Medicine information 

References

  1. 1.
    Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280:605–613PubMedCrossRefGoogle Scholar
  2. 2.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al (2002) Writing group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRefGoogle Scholar
  3. 3.
    Beral V (2003) Million Women Study Collaborators. Breat cancer and hormone replacement therapy in the Million Women Study. Lancet 362:419–427PubMedCrossRefGoogle Scholar
  4. 4.
    USPSTF (2003) Postmenopausal hormone replacement therapy for the primary prevention of chronic condition. Recommendations and rationale. U.S. Preventive Services Task Force. Am Fam Physician 67:358–364Google Scholar
  5. 5.
    The European Medicines Agency (2003) Public Statement on recent Publications regarding Hormone Replacement Therapy. EMEA [cited 2003 Dec 15]. Available from: http://www.emea.eu.int/pdfs/human/press/pus/3306503en.pdf
  6. 6.
    National Agency for Medicines, Social Insurance Institution. Finnish statistics on medicines, Helsinki: Edita Prima Oy, 1987–2005. ISSN 0786-2180Google Scholar
  7. 7.
    National Agency for Medicines, Social Insurance Institution (2006) Finnish statistics on medicines. Drug consumption January–June 2006. National Agency of Medicines; [cited 2006 Nov 8]. Available from: http://www.nam.fi/kulutus/kv_laakekulutus.htm
  8. 8.
    Apoteket. Läkemedelsutvecklingen - försäljingvolym januari-juni 2003. Apoteket; 2004 [cited 2004 January 8]. Available from: http://www.apoteket.se
  9. 9.
    Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291:47–53PubMedCrossRefGoogle Scholar
  10. 10.
    Lawton B, Rose S, McLeod D, Dowell A (2003) Changes in use of hormone replacement therapy after the report from the Women’s Health Initiative: cross sectional survey of users. Br Med J 327:845–846CrossRefGoogle Scholar
  11. 11.
    Usher C, Teeling M, Bennet K, Feely J (2006) Effect of clinical trial publicity on HRT prescribing in Ireland. Eur J Clin Pharmacol 24:1–4 Google Scholar
  12. 12.
    Levens E, Williams RS (2004) Current opinions and understandings of menopausal women about hormone replacement therapy (HRT)- the University of Florida experience. Am J Obstet Gynecol 191:641–647PubMedCrossRefGoogle Scholar
  13. 13.
    Walter FM, Emery JD, Rogers M, Britten N (2004) Women’s views of optimal risk communication and decision making in general practice consultations about the menopause and hormone replacement therapy. Patient Educ Couns 53:121–128PubMedCrossRefGoogle Scholar
  14. 14.
    Leppänen H-M, Ehkäisypillereiden käytön edut-ja haitat - tutkimus e-pillereiden käyttäjien kokemuksista [The benefits and adverse reactions of oral contraceptive users - users’ experiences]. Master’s thesis. Department of Social Pharmacy: University of Kuopio, 2001Google Scholar
  15. 15.
    Sihvo S, Ahonen R, Mikander H, Hemminki E (2000) Self-medication with vaginal antifungal drugs: physicians’ experiences and women’s utilization patterns. Fam Pract 17:145–149PubMedCrossRefGoogle Scholar
  16. 16.
    Veerus P, Hovi S-L, Fischer K, Rahu M, Hakama M, Hemminki E (2006) Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas 55:162–173PubMedCrossRefGoogle Scholar
  17. 17.
    Vainio KK, Airaksinen MS, Hyykky TT, Enlund KH (2002) Effect of therapeutic class on counselling in community pharmacies. Ann Pharmacother 36:781–786PubMedCrossRefGoogle Scholar
  18. 18.
    Herxheimer A (1989) Regulatory Approaches. The consumer viewpoint. In: Bogaert M, v.d. Stichele R, Kaufman J-M, Levebvre R (eds). Patient package inserts as a source of drug information. Amsterdam-New York-London: Excerpta Medica, pp 73–76. ISBN 0-444-81079-XGoogle Scholar
  19. 19.
    Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K (2004) Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140:184–188PubMedGoogle Scholar
  20. 20.
    Vihtamaki T, Savilahti R, Tuimala R (1999) Why do postmenopausal women discontinue hormone replacement therapy? Maturitas 33:99–105PubMedCrossRefGoogle Scholar
  21. 21.
    Oddens BJ, Boulet MJ (1997) Hormone replacement therapy among Danish women aged 45–65 years: prevalence, determinants, and compliance. Obstet Gynecol 90:269–277PubMedCrossRefGoogle Scholar
  22. 22.
    Sihvo S, Hemminki E (1997) Self-medication of dyspepsia: how appropriate is it? Scand J Gastroenterol 32:855–861PubMedCrossRefGoogle Scholar
  23. 23.
    Luoto R, Hemminki E, Kaaja R, Lindbohm M-L (2004) Hormonikorvaushoito ja kohdunpoisto [Hormone replacement therapy and hysterectomy]. In: Koponen P, Luoto R (eds). Lisääntymisterveys Suomessa [Reproductive health in Finland]. Terveys 2000-tutkimus. [The Health 2000 survey]. Helsinki: National Public Health Institute, pp 62–68. ISBN 951-740-422-0Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Miia J. Tiihonen
    • 1
    Email author
  • Anna-Mari Heikkinen
    • 2
  • Riitta S. Ahonen
    • 1
  1. 1.Department of Social PharmacyUniversity of KuopioKuopioFinland
  2. 2.Department of Gynecology and ObstetricsKuopio University HospitalKuopioFinland

Personalised recommendations